Recently, there have been efforts to reduce opioid use instead of increasing pain relief, and authors of a JAMA Viewpoint article argue that the movement to eliminate opioids for treating chronic pain is unnecessary.
An estimated 126 million adults in the United States have experienced some form of pain in the previous 3 months, and of them 25.4 million (11.2%) reported daily chronic pain and 23.4 million (10.3%) reported being in a lot of pain.
The chronic pain that is often experienced is prevalent, disabling, and costly; however, there have been greater efforts to reduce opioid use instead of working to increase pain relief, Kurt Kroenke, MD, of Indiana University School of Medicine, and Andrea Cheville, MD, of the Mayo Clinic, wrote in a JAMA Viewpoint article.
There has been a steady decrease in the analgesic options for chronic pain patients. Drugs like acetaminophen and nonsteroidal anti-inflammatory drugs have demonstrated a minimal efficacy for lower back pain, the leading cause of disability globally. The efficacy of multiple drug classes, like gabapentinoids and serotonin-norepinephrine reuptake inhibitors, remains unclear for treating broader chronic pain.
Opioid analgesics began to be used as an alternative for better pain management. However, as opioids became more common, the number of prescriptions, deaths from opioid overdose, and opioid misuse also increased. The authors suggest that the movement to eliminate opioids as an option for treating chronic pain as unnecessary since 5 to 8 million people in the United States use opioids for long-term pain management.
“Many patients currently receiving long-term opioids were started when opioids were still considered a viable treatment option and if satisfied with their pain control and using their medications appropriately should not be unilaterally compelled to wean off opioids,” the authors said.
The authors consider that only a very small proportion of opioid recipients transition to long-term opioid use. Of 10 million incident opioid recipients, by 1.5 years after the first prescription the probability of long-term use was 1.3%, 2.1% by 3 years, 3.7% by 6 years, and 5.3% by 9 years. Therefore, a minimal number of patients continue to use opioids for chronic pain and among those, the majority do not misuse the drug.
“An unintended consequence of excessive concerns raised about opioids could be an increasing reluctance among clinicians to prescribe even small amounts of opioids for a limited time for acute pain, including for patients discharged from the emergency department, those who are recuperating from surgical procedures, or persons with severe dental pain,” wrote the authors. “No clinician wants to be accused of contributing to the opioid “epidemic.” Meanwhile, some patients may be embarrassed about asking for effective pain relief.”
Despite the flaws among therapies for treating chronic pain, it is important to maintain options—even if only partially effective—in order to maximize the chances of managing chronic pain.
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More